News | Radiopharmaceuticals and Tracers | May 13, 2016

NorthStar Medical Radioisotopes Expanding University of Missouri Research Reactor Operations

Von Gahlen International to design and install new high-capacity filling line to quadruple molybdenum-99 dispensing capacity

May 13, 2016 — NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Mo., adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99).

NorthStar has contracted with Von Gahlen International Inc. to design and install the system, which will include a high-capacity DPharm unit to fill source vessels quickly, along with companion nuclear radiation containment chambers, or “hot cells.” Installation is scheduled to begin in November, with full operability targeted for the first half of 2017.

With the expansion, NorthStar is investing more than $3 million in its development of new processes for producing Mo-99 without the use of highly enriched uranium (HEU) and becoming the first producer of Mo-99 in the United States in more than 25 years.

Mo-99 is the parent isotope of technetium-99m (Tc-99m), the most widely used radioisotope in medical diagnostic imaging. It is used in approximately 40,000 procedures worldwide daily to diagnose and stage cancer, heart disease, infection, inflammation and other conditions.

Currently, all Mo-99 is produced overseas and most is produced in aging reactors using weapons-usable HEU, creating safety and national security concerns and the risk of product shortages. NorthStar is developing two non-uranium-based production processes that would help establish a domestic supply of Mo-99 and resolve the issues related to nuclear proliferation and the disposal of highly toxic radioactive waste.

In addition to significantly increasing dispensing capacity at MURR, the new filling line will be able to prepare source vessels containing Mo-99 generated from natural or enriched molybdenum-98 (Mo-98) targets. Enriched targets have higher concentrations of Mo-98 and produce approximately three times more Mo-99 than natural targets – 18-19 curies (Ci) compared to 6 Ci. A curie is a unit of radioactivity.

MURR will use the neutron capture production process being developed by NorthStar to supply Mo-99 through its Drug Master File. A Mo-98 target is bathed in neutrons, transforming a portion of it into Mo-99. The Mo-99 is extracted from the target and purified, and then moved to the NorthStar dispensing operation housed in the same facility. Waste created during Mo-99 production is minimal and relatively benign, making its disposal safe and inexpensive.

Source vessels are then filled with a Mo-99 solution using the DPharm and then shipped to customers for use with the RadioGenix isotope separation system. The RadioGenix system is used to extract the Tc-99m from the Mo-99, giving the radiopharmacy the key ingredient needed to create patient-ready doses of medical isotopes.

For more information: www.northstarnm.com

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging| September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging| August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging| August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging| June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging| April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging| January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging| January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging| January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init